Portal Home For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.
PROCRITline.com Reimbursement Excellence Centocor Ortho Biotech Inc.
Introduction Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT® (Epoetin alfa) Medicare Guideline Archives Medicare Guideline Update Table CMS 1450 / UB-04

State Medicare Guidelines / CMS 1500
Select



BILLING & REIMBURSEMENT

Medicare Guideline Update Table

Select State or Region




A

Alabama

Part A - Updated December 09, 2009

Part B - Updated December 03, 2009

Alaska

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010

Arizona

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010

Arkansas

Part A - Updated November 30, 2009

Part B - Updated November 30, 2009
Back to Top



C

California

Part A - Updated January 28, 2010

Part B - Updated January 28, 2010

Colorado

MAC - Updated February 05, 2010

Connecticut

Part A - Updated December 01, 2009

Part B - Updated December 01, 2009
Back to Top



D

Delaware

MAC - Updated December 12, 2008

District of Columbia

MAC - Updated November 16, 2009
Back to Top



F

Florida

Part A - Updated October 29, 2009

Part B - Updated October 29, 2009
Back to Top



G

Georgia

Part A - Updated December 09, 2009

Part B - Updated December 03, 2009
Back to Top



H

Hawaii

Part A - Updated January 28, 2010

Part B - Updated January 28, 2010
Back to Top



I

Idaho

Part A - Updated December 16, 2009

Part B - Updated October 01, 2009

Illinois

Part A - Updated December 01, 2009

Part B - Updated November 16, 2009

Indiana

Part A - Updated December 01, 2009

Part B - Updated December 01, 2009

Iowa

Part A - Updated November 16, 2009

Part B - Updated November 16, 2009
Back to Top



K

Kansas

Part A - Updated November 16, 2009

Part B - Updated November 16, 2009

Kentucky

Part A - Updated December 01, 2009

Part B - Updated December 01, 2009
Back to Top



L

Louisiana

Part A - Updated February 15, 2008

Part B - Updated November 30, 2009
Back to Top



M

Maine

Part A - Updated November 30, 2009

Part B - Updated November 30, 2009

Maryland

MAC - Updated December 12, 2008

Massachusetts

Part A - Updated November 30, 2009

Part B - Updated November 30, 2009

Michigan

Part A - Updated December 01, 2009

Part B - Updated November 16, 2009

Minnesota

Part A - Updated December 16, 2009

Part B - Updated November 16, 2009

Mississippi

Part A - Updated February 15, 2008

Part B - Updated January 01, 2010

Missouri

Part A - Updated November 16, 2009

Part B - Updated November 16, 2009

Montana

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010
Back to Top



N

Nebraska

Part A - Updated November 16, 2009

Part B - Updated November 16, 2009

Nevada

Part A - Updated January 28, 2010

Part B - Updated January 28, 2010

New Hampshire

Part A - Updated November 30, 2009

Part B - Updated November 30, 2009

New Jersey

MAC - Updated December 12, 2008

New Mexico

MAC - Updated February 05, 2010

New York

Part A - Updated December 01, 2009

Part B - Updated December 01, 2009

North Carolina

Part A - Updated July 01, 2008

Part B - Updated October 01, 2009

North Dakota

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010
Back to Top



O

Ohio

Part A - Updated December 01, 2009

Part B - Updated July 09, 2009

Oklahoma

MAC - Updated February 05, 2010

Oregon

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010
Back to Top



P

Pennsylvania

MAC - Updated December 12, 2008
Back to Top



R

Rhode Island

Part A - Updated November 30, 2009

Part B - Updated November 30, 2009
Back to Top



S

South Carolina

Part A - Updated July 01, 2008

Part B - Updated December 01, 2009

South Dakota

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010
Back to Top



T

Tennessee

Part A - Updated December 09, 2009

Part B - Updated December 03, 2009

Texas

MAC - Updated February 05, 2010
Back to Top



U

Utah

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010
Back to Top



V

Vermont

Part A - Updated November 30, 2009

Part B - Updated November 30, 2009

Virginia

Part A - Updated December 01, 2009

Part B - Updated February 05, 2010
Back to Top



W

Washington

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010

West Virginia

Part A - Updated December 01, 2009

Part B - Updated July 09, 2009

Wisconsin

Part A - Updated December 01, 2009

Part B - Updated November 16, 2009

Wyoming

Part A - Updated December 16, 2009

Part B - Updated January 13, 2010
Back to Top



Important Safety Information for PROCRIT® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:
  • In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

  • Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.
Cancer:
  • ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

  • To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

  • Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

  • Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

  • ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

  • Discontinue following the completion of a chemotherapy course.
Perisurgery: PROCRIT® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT® (Epoetin alfa)

Medication Guide for PROCRIT®
Please read the Medication Guide for PROCRIT® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT® injections at home.




CPT only © 2008 American Medical Association. All Rights Reserved.

CPT codes, descriptions and material only are copyright 2008 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS Restrictions Apply to Government Use.

Home  |  Subscribe  |  Survey  |  Procrit® Billing  |  Patient Resources  |  Key Links  |  Helpful Resources  |  FAQ
Prescribing Information  |  Glossary  |  Contact Us  |  Site Map

By using this site you agree to our Legal Notice and Privacy Policy.
This site is published by Centocor Ortho Biotech Inc. which is solely responsible for its contents. It is intended for visitors
from the United States of America. © Centocor Ortho Biotech Inc. 2010. Last modified: 02/05/2010